Immunocore Holdings (IMCR) Other Accumulated Expenses (2022 - 2024)

Immunocore Holdings (IMCR) has reported Other Accumulated Expenses for 3 consecutive years, with $7.5 million the latest figure, recorded in Q1 2024.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $7.5 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $7.5 million (changed N/A YoY) and the FY2023 annual result came in at $6.0 million, up 62.74% from the prior year.
• Other Accumulated Expenses advanced to $7.5 million in Q1 2024 per IMCR's latest filing, from $6.0 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for IMCR reached as high as $7.5 million in Q1 2024 and fell as low as $3.7 million in Q4 2022.
• A 3-year average of $5.7 million and a median of $6.0 million in 2023 frame the typical range for Other Accumulated Expenses.
• The largest YoY upside for Other Accumulated Expenses was 62.74% in 2023 against a maximum downside of 62.74% in 2023.
• Year by year, Other Accumulated Expenses stood at $3.7 million in 2022, then surged by 62.74% to $6.0 million in 2023, then increased by 24.49% to $7.5 million in 2024.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $7.5 million, $6.0 million, and $3.7 million for Q1 2024, Q4 2023, and Q4 2022 respectively.